• Je něco špatně v tomto záznamu ?

Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients

T. Jelínek, V. Maisnar, L. Pour, I. Špička, J. Minařík, E. Gregora, P. Kessler, M. Sýkora, H. Fraňková, D. Adamová, M. Wróbel, P. Mikula, J. Jarkovský, J. Diels, X. Gatopoulou, Š. Veselá, H. Besson, L. Brožová, T. Ito, R. Hájek,

. 2018 ; 34 (5) : 775-783. [pub] 20180215

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035514

OBJECTIVES: We conducted an adjusted comparison of progression-free survival (PFS) and overall survival (OS) for daratumumab monotherapy versus standard of care, as observed in a real-world historical cohort of heavily pretreated multiple myeloma patients from Czech Republic. METHODS: Using longitudinal chart data from the Registry of Monoclonal Gammopathies (RMG) of the Czech Myeloma Group, patient-level data from the RMG was pooled with pivotal daratumumab monotherapy studies (GEN501 and SIRIUS; 16 mg/kg). RESULTS: From the RMG database, we identified 972 treatment lines in 463 patients previously treated with both a proteasome inhibitor and an immunomodulatory drug. Treatment initiation dates for RMG patients were between March 2006 and March 2015. The most frequently used treatment regimens were lenalidomide-based regimens (33.4%), chemotherapy (18.1%), bortezomib-based regimens (13.6%), thalidomide-based regimens (8.0%), and bortezomib plus thalidomide (5.3%). Few patients were treated with carfilzomib-based regimens (2.5%) and pomalidomide-based regimens (2.4%). Median observed PFS for daratumumab and the RMG cohort was 4.0 and 5.8 months (unadjusted hazard ratio [HR], 1.14; 95% confidence interval [CI], 0.94-1.39), respectively, and unadjusted median OS was 20.1 and 11.9 months (unadjusted HR, 0.61; 95% CI, 0.48-0.78), respectively. Statistical adjustments for differences in baseline characteristics were made using patient-level data. The adjusted HRs (95% CI) for PFS and OS for daratumumab versus the RMG cohort were 0.79 (0.56-1.12; p = .192) and 0.33 (0.21-0.52; p < .001), respectively. CONCLUSIONS: Adjusted comparisons between trial data and historical cohorts can provide useful insights to clinicians and reimbursement decision makers on relative treatment efficacies in the absence of head-to-head comparison studies for daratumumab monotherapy.

b 4th Department of Internal Medicine Hematology Charles University Faculty Hospital and Faculty of Medicine Hradec Králové Czech Republic

c Department of Internal Medicine Hematology and Oncology University Hospital Brno and Faculty of Medicine Masaryk University Jihlavská 340 20 625 00 Brno Bohunice Brno Starý Lískovec Czech Republic

Department of Haematooncology University Hospital Ostrava and Faculty of Medicine and Faculty of Science University of Ostrava Poruba Czech Republic

Department of Hematology Hospital Novy Jicin Nový Jičín Czech Republic

Department of Internal Medicine Charles University Prague 1st Faculty of Medicine and General Teaching Hospital Hradec Králové Czech Republic

e Department of Hemato Oncology University Hospital Olomouc and Faculty of Medicine and Dentistry Palacky University Olomouc Olomouc Czech Republic

f Department of Internal Medicine and Hematology University Hospital Kralovske Vinohrady Praha Czech Republic

g Department of Hematology and Transfusion Medicine Pelhrimov Hospital Pelhřimov Czech Republic

h Department of Clinical Hematology Hospital Ceske Budejovice České Budějovice Czech Republic

i Department of Hematology General Hospital Liberec Liberec Czech Republic

j Department of Clinical Hematology Silesian Hospital Opava Opava Czech Republic

Janssen Health Economics and Market Access EMEA Statistics and Modelling Beerse Belgium

l Department of Clinical Hematology General Hospital Havirov Havířov Czech Republic

m Institute of Biostatistics and Analyses Faculty of Medicine and Faculty of Science Masaryk University Brno Czech Republic

o Janssen Health Economics and Market Access EMEA Athens Greece

p Janssen Cilag s r o Smíchov Anděl Czech Republic

q Janssen Health Economics and Market Access EMEA High Wycombe UK

r Department of Haematooncology University Hospital Ostrava and Faculty of Medicine University of Ostrava Ostrava Czech Republic

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035514
003      
CZ-PrNML
005      
20230714085532.0
007      
ta
008      
191007s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/03007995.2017.1410121 $2 doi
035    __
$a (PubMed)29172760
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Jelínek, Tomáš $u a Department of Haematooncology, University Hospital Ostrava and Faculty of Medicine and Faculty of Science , University of Ostrava , Poruba , Czech Republic.
245    10
$a Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients / $c T. Jelínek, V. Maisnar, L. Pour, I. Špička, J. Minařík, E. Gregora, P. Kessler, M. Sýkora, H. Fraňková, D. Adamová, M. Wróbel, P. Mikula, J. Jarkovský, J. Diels, X. Gatopoulou, Š. Veselá, H. Besson, L. Brožová, T. Ito, R. Hájek,
520    9_
$a OBJECTIVES: We conducted an adjusted comparison of progression-free survival (PFS) and overall survival (OS) for daratumumab monotherapy versus standard of care, as observed in a real-world historical cohort of heavily pretreated multiple myeloma patients from Czech Republic. METHODS: Using longitudinal chart data from the Registry of Monoclonal Gammopathies (RMG) of the Czech Myeloma Group, patient-level data from the RMG was pooled with pivotal daratumumab monotherapy studies (GEN501 and SIRIUS; 16 mg/kg). RESULTS: From the RMG database, we identified 972 treatment lines in 463 patients previously treated with both a proteasome inhibitor and an immunomodulatory drug. Treatment initiation dates for RMG patients were between March 2006 and March 2015. The most frequently used treatment regimens were lenalidomide-based regimens (33.4%), chemotherapy (18.1%), bortezomib-based regimens (13.6%), thalidomide-based regimens (8.0%), and bortezomib plus thalidomide (5.3%). Few patients were treated with carfilzomib-based regimens (2.5%) and pomalidomide-based regimens (2.4%). Median observed PFS for daratumumab and the RMG cohort was 4.0 and 5.8 months (unadjusted hazard ratio [HR], 1.14; 95% confidence interval [CI], 0.94-1.39), respectively, and unadjusted median OS was 20.1 and 11.9 months (unadjusted HR, 0.61; 95% CI, 0.48-0.78), respectively. Statistical adjustments for differences in baseline characteristics were made using patient-level data. The adjusted HRs (95% CI) for PFS and OS for daratumumab versus the RMG cohort were 0.79 (0.56-1.12; p = .192) and 0.33 (0.21-0.52; p < .001), respectively. CONCLUSIONS: Adjusted comparisons between trial data and historical cohorts can provide useful insights to clinicians and reimbursement decision makers on relative treatment efficacies in the absence of head-to-head comparison studies for daratumumab monotherapy.
650    _2
$a monoklonální protilátky $x terapeutické užití $7 D000911
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a kohortové studie $7 D015331
650    _2
$a lidé $7 D006801
650    _2
$a mnohočetný myelom $x farmakoterapie $7 D009101
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Česká republika $7 D018153
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Maisnar, Vladimír $u b 4th Department of Internal Medicine - Hematology, Charles University Faculty Hospital and Faculty of Medicine , Hradec Králové , Czech Republic.
700    1_
$a Pour, Luděk $u c Department of Internal Medicine, Hematology and Oncology , University Hospital Brno and Faculty of Medicine Masaryk University , Jihlavská 340/20, 625 00 Brno-Bohunice-Brno-Starý Lískovec , Czech Republic.
700    1_
$a Špička, Ivan $u d Department of Internal Medicine , Charles University in Prague, First Faculty of Medicine and General Teaching Hospital , Hradec Králové , Czech Republic.
700    1_
$a Minařík, Jiří $u e Department of Hemato-Oncology , University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc , Olomouc , Czech Republic.
700    1_
$a Gregora, Evžen $u f Department of Internal Medicine and Hematology , University Hospital Kralovske Vinohrady , Praha , Czech Republic.
700    1_
$a Kessler, Petr $u g Department of Hematology and Transfusion Medicine , Pelhrimov Hospital , Pelhřimov , Czech Republic.
700    1_
$a Sýkora, Michal $u h Department of Clinical Hematology , Hospital Ceske Budejovice , České Budějovice , Czech Republic.
700    1_
$a Fraňková, Hana $u i Department of Hematology , General Hospital Liberec , Liberec , Czech Republic.
700    1_
$a Adamová, Dagmar $u j Department of Clinical Hematology , Silesian Hospital Opava , Opava , Czech Republic.
700    1_
$a Wróbel, Marek $u Department of Hematology , Hospital Novy Jicin , Nový Jičín , Czech Republic. $7 xx0303976
700    1_
$a Mikula, Peter $u l Department of Clinical Hematology , General Hospital Havirov , Havířov , Czech Republic.
700    1_
$a Jarkovský, Jiří $u m Institute of Biostatistics and Analyses, Faculty of Medicine and Faculty of Science , Masaryk University , Brno , Czech Republic.
700    1_
$a Diels, Joris $u n Janssen Health Economics & Market Access EMEA Statistics & Modelling , Beerse , Belgium.
700    1_
$a Gatopoulou, Xenia $u o Janssen Health Economics & Market Access EMEA , Athens , Greece.
700    1_
$a Veselá, Šárka $u p Janssen - Cilag s.r.o. , Smíchov-Anděl , Czech Republic.
700    1_
$a Besson, Hervé $u n Janssen Health Economics & Market Access EMEA Statistics & Modelling , Beerse , Belgium.
700    1_
$a Brožová, Lucie $u m Institute of Biostatistics and Analyses, Faculty of Medicine and Faculty of Science , Masaryk University , Brno , Czech Republic.
700    1_
$a Ito, Tetsuro $u q Janssen Health Economics & Market Access EMEA , High Wycombe , UK.
700    1_
$a Hájek, Roman $u r Department of Haematooncology, University Hospital Ostrava and Faculty of Medicine , University of Ostrava , Ostrava , Czech Republic.
773    0_
$w MED00009520 $t Current medical research and opinion $x 1473-4877 $g Roč. 34, č. 5 (2018), s. 775-783
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29172760 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20230714085532 $b ABA008
999    __
$a ok $b bmc $g 1452174 $s 1074064
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 34 $c 5 $d 775-783 $e 20180215 $i 1473-4877 $m Current medical research and opinion $n Curr Med Res Opin $x MED00009520
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...